CLENIL ® Beclometasone

CLENIL ® is a drug based on Beclometasone Dipropionate

THERAPEUTIC GROUP: Drugs for obstructive airway disorders

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Indications CLENIL ® Beclometasone

CLENIL ® is indicated in the treatment of obstructive airway disorders such as asthma, allergic rhinitis, inflammatory diseases of the nasal cavities and of the rhinopharyngeal tract.

CLENIL ® is also indicated in the control of progression and symptomatology of asthmatic pathology.

CLENIL ® Beclometasone mechanism of action

CLENIL ® is a medicinal product based on Beclometasone dipropionate, a high activity synthetic corticosteroid, particularly effective for topical use.

Introduced by aerosol in fact Beclometasone is able to reduce the degree of local inflammation by inhibiting the production of inflammatory cytokines, prostaglandins and leukotrienes, thus determining a reduced degree of activation of the cellular elements of inflammation.

Antiallergic ones are added to the typical and characterized anti-inflammatory activity, important in reducing the histaminergic stimulus and the related congestive symptomatology associated with the intense vasodilatation of the mucous membranes that is observed in these cases and that is classically associated with mucosal edema.

Although the activity of Beclometasone is predominantly local, the modest share of systemically absorbed drug does not produce significant clinical effects, first suffering a hepatic metabolism and subsequently an elimination via the biliary and urinary tract.

Studies carried out and clinical efficacy

BECLOMETASONE IN THE TREATMENT OF ALLERGIC RITES

Allergy Asthma Proc. 2013 Nov; 34 (6): 534-41. doi: 10.2500 / aap.2013.34.3707.

Meltzer EO, Korenblat PE, Lanier BQ, Kelley L, Tantry SK.

Recent work that demonstrates how Beclometasone dipropionate represents a valid therapeutic ally in the management of allergic rhinitis, although the dosages used are often not optimized given the pharmaceutical formats available on the market.

BECLOMETASONE IN PREGNANCY

Allergol Immunopathol (Madr). 2013 Jul 2. pii: S0301-0546 (13) 00153-5. doi: 10.1016 / j.aller.2013.03.009. [Epub ahead of print]

de Aguiar MM, from Silva HJ, Rizzo JA, Leite DF, Silva Lima ME, Sarinho ES.

Metanalysis study evaluating the use of Beclometasone in asthmatic women during pregnancy. Of the nine selected articles only one demonstrates the risk of congenital malformations while another of metabolic endocrine disorders in the unborn child, associated with the consumption of this corticosteroid.

BECLOMETASONE IN ALLERGIC SEASONAL RINITE

Ann Allergy Asthma Immunol. 2013 Nov; 111 (5): 408-414.e1. doi: 10.1016 / j.anai.2013.07.033. Epub 2013 Aug 28.

Storms WW, Segall N, Mansfield LE, Amar NJ, Kelley L, Ding Y, Tantry SK.

Study demonstrating the efficacy and excellent tolerability of Beclomethasone in the treatment of seasonal allergic rhinitis in small patients aged between 6 and 11 years.

Method of use and dosage

CLENIL ®

Suspension to be nebulized from 0.04 gr of Beclometasone dipropionate per 100 ml of suspension.

The definition of the dosing schedule and the timing of administration of the drug belongs to the doctor after a careful assessment of the patient's general health conditions and a correct classification of the relative clinical conditions.

Generally the most used dosage in adults is that of a single-dose vial per aerosol session 1 or 2 times a day

Warnings CLENIL ® Beclometasone

CLENIL ® therapy should be carefully supervised by your doctor in order to best characterize the therapeutic efficacy of the same and the possible presence of potential adverse reactions.

It should be remembered that the use of corticosteroids, especially if prolonged over time, could lead to the appearance of adverse reactions both local and systemic, such as to require the suspension of treatment.

Any overlap of bacterial infections of the upper respiratory tract should be treated with adequate antibiotic therapy.

It should be remembered that the use of Corticosteroids, without clinical necessity, is prohibited in and out of the race.

It is recommended to keep the medicine out of the reach of children.

PREGNANCY AND BREASTFEEDING

Given the potential side effects of Corticosteroids for the health of the fetus and infant, it is appropriate to extend the aforementioned contraindications to the use of CLENIL ® also to pregnancy and the subsequent breastfeeding period.

Interactions

Drug interactions worthy of clinical note are currently unknown.

Contraindications CLENIL ® Beclometasone

The use of CLENIL ® is contraindicated in patients with hypersensitivity to the active ingredient or to one of its excipients, in patients suffering from active or quiescent viral and tuberculosis infections and in pregnant and lactating women.

Undesirable effects - Side effects

Therapy with CLENIL ®, especially if continued for a long time, could determine the appearance of candidiasis of the mouth and throat, cough and hoarseness.

Fortunately the systemic adverse reactions typical of corticosteroids worthy of clinical note are rarer.